3
Foundation Complete Program provided a comprehensive genomic profiling both form Tissue and Liquid as a initial test and offer a 2 free test for monitoring in patient which need to explore on the heterogeneity of cancer and monitoring after the progression
*only for Private Hospital
Tissue biopsy may not capture the genomic landscape
of a patient's entire tumour burden
Keep in mind: The genomic landscape of a cancer evolves over time,
hence archival tissue may not fully represent the tumour genotype at progression
19 Scherer, F. (2020) in Recent Results in Cancer Research: Tumor Liquid Biopsies. Springer.
Alterations detected in ctDNA are generally concordant
with those in temporally-matched tissue
Concordance on positives between tissue and ctDNA was generally high for short variants*.
However, some alterations were only identified in ctDNA, suggesting that liquid biopsy may capture tumour heterogeneity1-4
Point mutations and short insertions and deletions.
CLONA: circulating tumour DANN; GI: gastrointestinal.
1. Chung, J. H., et al. (2017) Ann Oncol 28:2866-73: 2. Schrock, A.B., et al. (2018) Clin Cancer Res 24(3):1881-90:
3. Clark, TA., et al. (2018) J Mol Diagn 20(5):686-702: 4. Shu, Y., et al. (2017) Sci Rep 7:583.